Livzon Pharmaceutical Group Class H ((LVZPF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Livzon Pharmaceutical Group is currently conducting a Phase II clinical study titled ‘A Multicenter, Randomized, Open-label, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of H001 Capsules in the Prevention of Venous Thromboembolism (VTE) in Subjects Undergoing Total Knee Arthroplasty.’ This study aims to assess the efficacy and safety of H001 capsules in preventing venous thromboembolism in patients undergoing total knee arthroplasty, a significant concern in circulatory disease management.
The study tests various dosages of H001 capsules, including 200mg once daily, 300mg once daily, and 200mg twice daily, against the active comparator, Enoxaparin Sodium Injection. These interventions are designed to prevent blood clots post-surgery, potentially offering a new oral treatment option.
The study is designed as a multicenter, randomized, open-label trial with a parallel intervention model and no masking, focusing primarily on treatment. This straightforward design aims to provide clear insights into the treatment’s effectiveness compared to existing options.
Key dates for this study include its start date on April 30, 2025, which marks the beginning of participant recruitment. The primary completion and estimated study completion dates are yet to be announced, but the last update was also on April 30, 2025, indicating active progress.
For investors, the successful development of H001 capsules could enhance Livzon Pharmaceutical Group’s market position, potentially boosting its stock performance. The study’s progress and outcomes will be closely watched by investors and competitors in the pharmaceutical industry, as it could influence market dynamics in the treatment of circulatory diseases.
The study is currently ongoing, with further details available on the ClinicalTrials portal.